Everything below concerns circadian clock. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Lord Robert Cecil on 2 December 1917, assured an audience that the government fully intended that "Judea [was] for the Jews." Yair Auron opines that Cecil, then a deputy Foreign Secretary representing the British Government at a celebratory gathering of the English Zionist Federation, "possibly went beyond his official brief" in saying (he cites Stein) "Our wish is that Arabian countries shall be for the Arabs, Armenia for the Armenians and Judaea for the Jews". The following October Neville Chamberlain, while chairing a Zionist meeting, discussed a "new Jewish State." At the time, Chamberlain was a Member of Parliament for Ladywood, Birmingham; recalling the event in 1939, just after Chamberlain had approved the 1939 White Paper, the Jewish Telegraph Agency noted that the Prime Minister had "experienced a pronounced change of mind in the 21 years intervening" A year later, on the Declaration's second anniversary, General Jan Smuts said that Britain "would redeem her pledge ... and a great Jewish state would ultimately rise." In similar vein, Churchill a few months later stated:
Glutathione S-transferase A3 is an enzyme that in humans is encoded by the GSTA3 gene. Cytosolic and membrane-bound forms of glutathione S-transferase are encoded by two distinct supergene families. These enzymes are involved in cellular defense against toxic, carcinogenic, and pharmacologically active electrophilic compounds. At present, eight distinct classes of the soluble cytoplasmic mammalian glutathione S-transferases have been identified: alpha, kappa, mu, omega, pi, sigma, theta and zeta. This gene encodes a glutathione S-transferase belonging to the alpha class genes that are located in a cluster mapped to chromosome 6. Genes of the alpha class are highly related and encode enzymes with glutathione peroxidase activity. However, during evolution, this alpha class gene diverged accumulating mutations in the active site that resulted in differences in substrate specificity and catalytic activity. The enzyme encoded by this gene catalyzes the double bond isomerization of precursors for progesterone and testosterone during the biosynthesis of steroid hormones. An additional transcript variant has been identified, but its full length sequence has not been determined.
The September 11 attacks, colloquially known as 9/11, were a coordinated series of suicide attacks perpetrated by the Islamic terrorist organization al-Qaeda against the United States in 2001. A total of 19 hijackers commandeered four commercial passenger airliners. The first two planes were flown into each of the Twin Towers at the World Trade Center in New York City, while the third plane crashed into the Pentagon, the headquarters of the United States Department of Defense, in Arlington County, Virginia. The fourth plane crashed in a rural field in Pennsylvania during a passenger revolt. The ringleader, Mohamed Atta, flew American Airlines Flight 11 into the North Tower of the World Trade Center at 8:46 a.m. At 9:03 a.m. Marwan al-Shehhi flew United Airlines Flight 175 into the South Tower. Both collapsed within an hour and forty-two minutes, destroying the remaining five structures in the complex. Hani Hanjour flew American Airlines Flight 77 into the Pentagon at 9:37 a.m., causing a partial collapse. United Airlines Flight 93, hijacked by Ziad Jarrah, was believed to target either the United States Capitol or the White House. Alerted to the previous attacks, the passengers revolted and the hijackers crashed the aircraft into a field near Shanksville, Pennsylvania, at 10:03 a.m. The Federal Aviation Administration ordered a ground stop for all traffic in U.S. airspace, requiring all airborne aircraft to return to their point of origin or divert to Canada.
In case of cGMP fine chemicals, process validation is also required. This consists of the three elements: process design, process qualification and continued process verification. Once a new chemical process has been introduced successfully on an industrial scale, process optimization is called upon to improve the economics. As a rule of thumb, it should be attempted to reduce the costs of goods sold (COGS) by 10-20%, every time the yearly production quantity has doubled. The task extends from fine tuning the currently used synthetic method all the way to the search for an entirely different second generation process. Specific provisions include the increase of overall yield, the reduction of the number of steps, raw material cost, solvent, catalyst, enzyme consumption, environmental impact.
Sources: en.wikipedia.org
== Occurrence == Gamma PGA is made by a number of Bacillus species. The best-known source is natto, where it is produced by Bacillus subtilis. It is also an important component of the Bacillus anthracis capsule, hiding the bacterium from the immune system and allowing it to grow unchecked.
== Treatment == Healthcare providers may recommend lifelong heart-healthy lifestyle choices. These choices included a heart-healthy eating plan, physical activity, quitting smoking, improved sleep hygiene, weight loss, blood pressure control, cholesterol control, blood pressure control, and stress management. Some medications may be prescribed to allow the blood vessels to widen and help the heart pump include ACE inhibitors, beta blockers, calcium channel blockers, nitrates, and Ranolazine. Some medications may be prescribed to manage cholesterol include statins, nonstatins, and fribrates. Some medications may be prescribed for other risk factors for heart disease like blood sugar and obesity such as empagliflozin, canagliflozin, metformin, liraglutide, orlistat, and semaglutide. Heart surgery may be needed to treat this condition. Some procedures include percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and transmyocardial laser revascularization (coronary endarterectomy). Preventative procedures like bariatric surgery can help lower coronary heart disease risk.
== Synthesis == Two separate syntheses of thiotepa have been described in literature. The most prevalent method involves the addition of an excess of aziridine to thiophosphoryl chloride in the presence of a base such as triethylamine (TEA) (or another molar equivalent of aziridine) and a suitable solvent (e.g., ether or benzene). The first molecule of aziridine reacts with thiophosphoryl chloride to produce dichloridophosphorothionate, which is sufficiently reactive due to the poor overlap of the nitrogen lone pair with the P=S bond, allowing it to react with another two molecules of aziridine
Hegseth ordered the supercarrier USS Gerald R. Ford deployed to Latin America on 24 October. According to The Washington Post, it is "the world's largest aircraft carrier" and its deployment "signaled a major expansion of [the] military campaign against 'Transnational Criminal Organizations' in Latin America". The New York Times reported it "carries about 5,000 sailors and has more than 75 attack, surveillance and support aircraft, including F/A-18 fighters". The Ford's full air wing is reportedly embarked. Though its escort typically includes five Arleigh Burke class destroyers—USS Winston S. Churchill, USS Bainbridge, USS Mahan, USS Forrest Sherman and USS Mitscher—as of 8 November the USS Forrest Sherman and Mitscher were still operating independently in other areas of the globe (such as the Red Sea). On 26 October, a Russian Il-76 transport aircraft under US sanctions landed in Venezuela "after a circuitous route over Africa to avoid Western airspace, according to Flightradar24". The aircraft carried Pantsir-S1 and Buk-M2E air defense systems, according to a Russian official. As of 31 October, Gettysburg (CG-64), another guided missile cruiser, had joined the fleet.
==== pH ==== Cellular proteins are held in a relatively constant pH in order to prevent changes in the protonation state of amino acids. If the pH drops, some amino acids in the polypeptide chain can become protonated if the pKa of their R groups is higher than the new pH. Protonation can change the charge these R groups have. If the pH raises, some amino acids in the chain can become deprotonated (if the pKa of the R group is lower than the new pH). This also changes the R group charge. Since many amino acids interact with other amino acids based on electrostatic attraction, changing the charge can break these interactions. The loss of these interactions alters the proteins structure, but most importantly it alters the proteins function, which can be beneficial or detrimental. A significant change in pH may even disrupt many interactions the amino acids make and denature (unfold) the protein.
Sources: en.wikipedia.org
However, the organism makes antibodies against this viral protein, and those antibodies also kill the human ACTH hormone, which leads to the suppression of adrenal gland function. Such adrenal suppression is a way for a virus to evade immune detection and elimination. This viral strategy can have severe consequences for the host (human that is infected by the virus), as cortisol is essential for regulating various physiological processes, such as metabolism, blood pressure, inflammation, and immune response. A lack of cortisol can result in a condition called adrenal insufficiency, which can cause symptoms such as fatigue, weight loss, low blood pressure, nausea, vomiting, and abdominal pain. Adrenal insufficiency can also impair the ability of the host to cope with stress and infections, as cortisol helps to mobilize energy sources, increase heart rate, and downregulate non-essential metabolic processes during stress. Therefore, by suppressing cortisol production, some viruses can escape the immune system and weaken the host's overall health and resilience.
Benzodiazepines are usually administered orally; however, very occasionally lorazepam or diazepam may be given intravenously for the treatment of panic attacks. Because of their effectiveness, tolerability, and rapid onset of anxiolytic action, benzodiazepines are frequently used for the treatment of anxiety associated with panic disorder. However, there is disagreement among expert bodies regarding the long-term use of benzodiazepines for panic disorder. The views range from those holding benzodiazepines are not effective long-term and should be reserved for treatment-resistant cases to those holding they are as effective in the long term as selective serotonin reuptake inhibitors (SSRIs). American Psychiatric Association (APA) guidelines, published in January 2009, note that, in general, benzodiazepines are well tolerated, and their use for the initial treatment for panic disorder is strongly supported by numerous controlled trials. APA states that there is insufficient evidence to recommend any of the established panic disorder treatments over another. The choice of treatment between benzodiazepines, SSRIs, serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, and psychotherapy should be based on the patient's history, preference, and other individual characteristics. Selective serotonin reuptake inhibitors are likely to be the best choice of pharmacotherapy for many patients with panic disorder, but benzodiazepines are also often used, and some studies suggest that these medications are still used with greater frequency than the SSRIs.
== History == In a multi-center, randomized trial in participants with active Graves' ophthalmopathy, teprotumumab was more effective than placebo. In February 2019, Horizon announced results from a Phase III confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED). The study met its primary endpoint, showing more participants treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9% of teprotumumab participants compared to 9.5% of placebo participants achieved the primary endpoint of a 2 mm or more reduction in proptosis (p<0.001). Proptosis is the main cause of morbidity in TED. All secondary endpoints were also met and the safety profile was consistent with the Phase II study of teprotumumab in TED. In July 2019, Horizon submitted a biologics license application to the US Food and Drug Administration (FDA) for teprotumumab for the treatment of active thyroid eye disease. Teprotumumab was first investigated for the treatment of solid and hematologic tumors, including breast cancer, Hodgkin's and non-Hodgkin's lymphoma, non-small cell lung cancer, and sarcoma. Teprotumumab-trbw was approved based on the results of two clinical trials (Trial 1/ NCT01868997 and Trial 2/ NCT03298867) of 170 subjects with active TED who were randomized to either receive teprotumumab-trbw or a placebo.
== History == Curcumin was named in 1815 when Henri Auguste Vogel and Pierre Joseph Pelletier reported the first isolation of a "yellow coloring-matter" from the rhizomes of turmeric. Later, it was found to be a mixture of resin and turmeric oil. In 1910, Milobedzka and Lampe reported the chemical structure of curcumin to be as diferuloylmethane. Later in 1913, the same group accomplished the synthesis of the compound. Although used in traditional medicine, the possible therapeutic properties of turmeric or curcumin remain undetermined.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.